Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Overview
• United States
  • Changes to Medicare Part D in 2008
  • FDA Amendments Act
  • Payers Ready to Promote Use of Biogenerics
  • Wal-Mart Expands Low-Priced Generics Range
  • Generics Mitigate Drug Infl ation
• European Union
  • First Biosimilar Epoetin Alfa Products Approved
• France
  • Emergency Pharmaceutical Cost-Containment Measures
  • Pressure for Further Cost Containment in the 2008 Budget
• Germany
  • Market Trends
  • Generics Manufacturers Under Pressure Despite Strong Demand For Their Products
  • Continued Growth in Rebate Contracts
  • Growing Demand for Copayment-Exempt Medicines
  • Abolition of Bonus-Malus Rule
• Italy
  • Increased Focus on Innovation in Reimbursement Decision Making
• Spain
  • Impact of the 2006 Medicines Law on Older Drugs
  • Guidance on Innovations of Therapeutic Interest
  • Restrictions on Generics Substitution
• United Kingdom
  • Government Plans to Replace the Pharmaceutical Price Regulation Scheme
  • Judicial Review of Initiatives to Promote Drug Switching
• Japan
  • Proposals for Reform of the Pricing and Reimbursement System
  • Steady Growth in Demand For Generics Despite Physician Reservations
• Outlook and Implications for the Pharmaceutical Industry

Tables and Figures

Tables

• 1. Medicare Part D: Key Parameters of the Standard Drug Benefi t Design, 2006-2008
• 2. Impact of Key Factors on Changes in German Statutory Health Insurance Funds' Pharmaceutical Expenditures, 2005-2008 (projected)
• 3. Projected Changes in German Statutory Health Insurance Spending on Pharmaceuticals, 2007-2008
• 4. Select Drugs Excluded from Generics Substitution in Spain
• 5. Proposed New Japanese Pharmaceutical Premium System Suggested by the Federation of Pharmaceutical Manufacturers Associations of Japan

Figures

• 1. Standard Medicare Part D Drug Benefi t Design, 2008
• 2. Annual Deductible Policies of Standalone Medicare Prescription Drug Plans, 2006-2008
• 3. Annual Deductible Policies of Medicare Advantage Plans, 2006-2008
• 4. Coverage Gap Policies of Standalone Medicare Prescription Drug Plans, 2006-2008
• 5. Detailed Coverage Gap Policies of Standalone Medicare Prescription Drug Plans, 2008
• 6. Coverage Gap Policies of Medicare Advantage Plans, 2006-2008
• 7. Detailed Coverage Gap Policies of Medicare Advantage Plans, 2008
• 8. Managed Care Organizations' Coverage of Omnitrope
• 9. HMO Pharmacy Directors' Views on Main Drivers of Biogeneric Usage in the United States
• 10. HMO Pharmacy Directors' Views on Likely Strategies for Promoting Biogeneric Usage
• 11. Projected Savings From Emergency Pharmaceutical Cost-Containment Measures in France
• 12. Percentage Decrease in Weighted Average Retail Prices of Eight Best-Selling Off-Patent Drugs in Germany, March 2006 Through April 2007
• 13. Structure of the German Pharmaceutical Market, First Half of 2007
• 14. Japanese Physicians' Views on Defi ciencies of the Japanese Generics Market